Company Filing History:
Years Active: 2022
Title: Martin John Perry: Innovator in Cancer Treatment
Introduction
Martin John Perry is a notable inventor based in Windsor, Berkshire, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development.
Latest Patents
Perry holds a patent for a groundbreaking invention titled "Treatment of cancer by stimulation of IL-12 production." This invention relates to a compound and composition designed to stimulate IL-12 production and IFN-γ production. The specific compounds involved include tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate, or a pharmaceutically acceptable salt, hydrate, or solvate thereof; and N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alanine. This patent highlights his commitment to advancing medical science and improving cancer treatment options.
Career Highlights
Perry is associated with Macrophage Pharma Limited, where he continues to work on innovative solutions in the pharmaceutical industry. His dedication to research and development has positioned him as a key figure in the fight against cancer.
Collaborations
Throughout his career, Perry has collaborated with esteemed colleagues, including David Festus Charles Moffat and Stephen Mark Anderton. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.
Conclusion
Martin John Perry's contributions to cancer treatment through his innovative patent demonstrate his commitment to improving healthcare. His work at Macrophage Pharma Limited and collaborations with other professionals underscore the importance of teamwork in scientific advancements.